Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.65 |
| ▸ | CDK2 | P24941 | 4/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | APLNR | P35414 | 4/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372126 | 0.85 | CCNA2 (0.61) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL29464255 | 0.83 | PTH1R (0.55) | CCNA2CDK2CCNA1PTH1R | |
| SCHEMBL30122771 | 0.83 | CCNA2 (0.64) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL29702256 | 0.81 | CCNA2 (0.69) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL29358777 | 0.81 | NPY1R (0.57) | CCNA2CDK2CDK4CCND1NPY1R | |
| SCHEMBL29393138 | 0.81 | BACE1 (0.61) | CCNA2CDK2AGTR1AGTR2CDK4 | |
| SCHEMBL29392502 | 0.81 | BACE1 (0.61) | CCNA2CDK2AGTR1AGTR2CDK4 | |
| SCHEMBL29419646 | 0.81 | CCNA2 (0.58) | CCNA2CDK2CCNA1APLNRPTH1R | |
| SCHEMBL23083920 | 0.80 | CCNA2 (0.58) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL30607220 | 0.78 | BACE1 (0.65) | CCNA2CDK2CCNA1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968583-B1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE BY MEANS OF A SEQUENCE-SPECIFIC TRANSPEPTIDASE ENZYME | NBE THERAPEUTICS AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-11986535-B2 | Method of producing an immunoligand/payload conjugate | NBE THERAPEUTICS AG (CH) | 2024-05-21 | — | — | US | disclosed |
| US-20220378927-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | NBE THERAPEUTICS AG (CH) | 2022-12-01 | — | — | US | disclosed |
| US-11364301-B2 | Method of producing an immunoligand/payload conjugate | NBE-THERAPEUTICS AG (CH) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378927-A1 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | DNPEP, FOLH1, ENGASE | CCNA2 4041/4885CDK2 4800/4885CCNA1 4358/4885 |
| US-11986535-B2 | Method of producing an immunoligand/payload conjugate | AGBL2, FOLH1, FCGR3B | CCNA2 3642/4885CDK2 4663/4885CCNA1 4353/4885 |
| US-11364301-B2 | Method of producing an immunoligand/payload conjugate | AGBL2, FOLH1, FCGR3B | CCNA2 3642/4885CDK2 4663/4885CCNA1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.